PRNP抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue lysate, Primary antibody: P02235(PRNP Antibody) at dilution 1/1200, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P02235(PRNP Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

PRNP antibodies target the prion protein (PrP), encoded by the PRNP gene, which is central to prion diseases—a group of fatal neurodegenerative disorders including Creutzfeldt-Jakob disease (CJD) and scrapie. Normal cellular PrP (PrP^C) is a glycoprotein expressed in neurons and other tissues, though its exact physiological role remains unclear. In prion diseases, PrP^C undergoes a conformational change into an abnormal, protease-resistant isoform (PrP^Sc), which aggregates and propagates disease through templated misfolding.

PRNP antibodies are critical tools for detecting and differentiating PrP^C and PrP^Sc in research and diagnostics. They enable the identification of prion deposits in tissues, study of protein misfolding mechanisms, and screening for therapeutic interventions. Specific monoclonal antibodies (e.g., 3F4. 6H4) recognize distinct epitopes, aiding in distinguishing prion strains or genetic variants linked to disease susceptibility. Some antibodies selectively bind PrP^Sc conformations, enhancing diagnostic accuracy.

Additionally, PRNP antibodies have therapeutic potential. Experimental studies explore their ability to block PrP^Sc propagation or promote clearance, though challenges like blood-brain barrier penetration persist. Their development also supports understanding PRNP mutations associated with inherited prion disorders. Overall, PRNP antibodies are indispensable in advancing prion biology, diagnostics, and emerging treatments.